Press release
Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse
Hepatitis D Pipeline Analysis
According to DelveInsight, the Hepatitis D treatment pipeline includes over six leading companies actively engaged in the development of more than six therapeutic candidates.
Hepatitis D Overview:
Hepatitis D, also known as delta hepatitis, is a liver infection caused by the hepatitis D virus (HDV) and occurs only in individuals already infected with the hepatitis B virus (HBV). Transmission happens through contact with infected blood or bodily fluids. The infection can be either acute and short-lived or develop into a chronic condition, often resulting in serious health issues, including permanent liver damage and potentially death. Individuals may contract hepatitis B and D at the same time (coinfection) or acquire hepatitis D after an existing hepatitis B infection (superinfection). Although there is no vaccine specifically for hepatitis D, vaccination against hepatitis B effectively prevents HDV infection as well.
Request for a detailed insights report on Hepatitis D pipeline insights [https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Hepatitis D Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatitis D Therapeutics Market.
Key Takeaways from the Hepatitis D Pipeline Report
*
DelveInsight's Hepatitis D pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hepatitis D treatment.
*
In October 2025, Bluejay Therapeutics announces upcoming data presentations on Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at the 2025 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting Registered .
*
In September 2023, Eiger BioPharmaceuticals announced the discontinuation of its Phase III LIMT-2 study of peginterferon lambda in patients with chronic hepatitis D. This decision was made following a recommendation from the Data Safety Monitoring Board (DSMB) after their routine safety review.
*
Key Hepatitis D companies such as Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, SomaGenics, Vir Biotechnology, VLP Biotech, and others are evaluating new drugs for Hepatitis D to improve the treatment landscape.
*
Promising Hepatitis D pipeline therapies in various stages of development include Lonafarnib, JNJ 73763989, and others.
Hepatitis D Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Hepatitis D Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hepatitis D market.
Download our free sample page report on Hepatitis D pipeline insights [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hepatitis D Emerging Drugs
*
Lonafarnib: Eiger Biopharmaceuticals
*
JNJ 73763989: Arrowhead Pharmaceuticals
Hepatitis D Companies
Approximately six major companies are working on developing treatments for Hepatitis D. Among them, Eiger Biopharmaceuticals has the most advanced drug candidates, currently in Phase III of clinical development.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Hepatitis D Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hepatitis D Therapies and Key Companies: Hepatitis D Clinical Trials and advancements [https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hepatitis D Pipeline Therapeutic Assessment
- Hepatitis D Assessment by Product Type
- Hepatitis D By Stage
- Hepatitis D Assessment by Route of Administration
- Hepatitis D Assessment by Molecule Type
Download Hepatitis D Sample report to know in detail about the Hepatitis D treatment market @ Hepatitis D Therapeutic Assessment [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Hepatitis D Current Treatment Patterns
4. Hepatitis D - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatitis D Late-Stage Products (Phase-III)
7. Hepatitis D Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatitis D Discontinued Products
13. Hepatitis D Product Profiles
14. Hepatitis D Key Companies
15. Hepatitis D Key Products
16. Dormant and Discontinued Products
17. Hepatitis D Unmet Needs
18. Hepatitis D Future Perspectives
19. Hepatitis D Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Hepatitis D Pipeline Reports Offerings [https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-d-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-eiger-biopharmaceuticals-arrowhead-pharmaceuticals-antios-therapeutics-pharmaesse]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse here
News-ID: 4082284 • Views: …
More Releases from ABNewswire
MedSpaAZ Announces Transformative Facial Spa Services in Chandler to Elevate Ski …
Living in Chandler, Arizona, is a sun-lover's dream. But let's be real-your skin pays the price. Constant exposure to desert air, harsh UV rays, and urban pollution can leave your complexion dull, dehydrated, and aging faster than you'd like.
So, how do you fight back? Sure, skincare products help, but if you want results, facial spa service in Chandler [https://medspaaz.com/facials-phoenix-az/] is where the magic happens.
And not just a one-time spa day.…
Chronic Inducible Urticaria Clinical Trials, Companies, Therapeutic Assessment, …
"DelveInsight's, "Chronic Inducible Urticaria - Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chronic Inducible Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Inducible Urticaria Pipeline constitutes 4+ key companies…
Krabbe Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Tr …
Krabbe Disease companies are Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others.
According to DelveInsight, the Krabbe Disease pipeline includes over eight leading companies actively engaged in developing more than eight treatment therapies for the condition.
Krabbe Disease Overview:
Krabbe disease…
UBrothers Construction Sets the Standard for Reliable Siding Contractors in Bost …
UBrothers Construction Sets the Standard for Reliable Siding Contractors in Boston
To safeguard your home against New England's capricious weather, siding contractors in Boston stand as your guard against the elements. Boston's weather, characterized by cold winters, warm summers, and ocean coastal storms, demands tough siding that is resistant to pressure. Protection aside, the right siding ensures curb appeal, optimized energy efficiency, and increases your property value.
Employing siding experts in Boston…
More Releases for Hepatitis
Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available…
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and…
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot
The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each…
